Valuation: Shield Therapeutics plc

Market Cap 32.63M 42.75M 38.93M 35.87M 61.22M 3.96B 64.34M 437M 174M 2.16B 160M 157M 6.79B P/E 2026 *
-
P/E 2027 * 2.05x
Enterprise Value 53.92M 70.63M 64.33M 59.28M 101M 6.54B 106M 721M 287M 3.57B 265M 259M 11.21B EV / Sales 2026 *
1.21x
EV / Sales 2027 * 1.08x
Free-Float
38.5%
Yield 2026 *
-
Yield 2027 * -
1 week-4.69%
Current month-46.02%
1 month-45.05%
3 months-37.76%
6 months-53.08%
Current year-69.04%
1 week 2.8
Extreme 2.8
3.2
1 month 2.8
Extreme 2.8
5.8
Current year 2.8
Extreme 2.8
12.5
1 year 2.8
Extreme 2.8
12.5
3 years 1.06
Extreme 1.0625
12.5
5 years 1.06
Extreme 1.0625
52
10 years 1.06
Extreme 1.0625
202
Manager TitleAgeSince
Chief Executive Officer 64 2024-07-23
Director of Finance/CFO 50 2026-08-31
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 68 2016-01-31
Chairman 70 2020-06-17
Director/Board Member 59 2020-06-25
Date Insider Type Main position Quantity % Market Cap. Importance
10/14/25 Free

Chief Executive Officer

1,547,262 0.1485%
2/13/25 Free

Chief Executive Officer

5,000,000 0.4800%
2/13/25 Buy

Chief Executive Officer

575,000 0.0552%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-4.69%-54.81%-49.59% 42.75M
-0.30%-6.68%+29.12%+125.42% 1,200B
+1.25%-5.35%+33.19%+80.42% 651B
+0.94%-2.99%+24.73%+106.93% 506B
-0.60%-1.95%+27.26%+67.32% 377B
+0.69%-9.50%+40.80%+30.23% 330B
+0.41%-4.70%+27.23%+51.59% 288B
+0.81%-4.08%-1.74%+32.71% 272B
-0.15%-6.45%+29.63%+64.18% 236B
-0.06%-0.98%+33.15%+118.99% 206B
Average +0.33%-4.75%+18.86%+62.82% 407B
Weighted average by Cap. +0.40%-5.19%+28.03%+87.49%

Financials

2026 *2027 *
Net sales 44.57M 58.38M 53.17M 49M 83.61M 5.41B 87.88M 596M 237M 2.95B 219M 214M 9.27B 53.22M 69.71M 63.49M 58.5M 99.83M 6.45B 105M 712M 283M 3.53B 262M 256M 11.06B
Net income -2.91M -3.81M -3.47M -3.2M -5.45M -353M -5.73M -38.89M -15.46M -193M -14.28M -13.98M -604M 6.48M 8.49M 7.74M 7.13M 12.17M 787M 12.79M 86.76M 34.48M 430M 31.87M 31.2M 1.35B
Net Debt 21.29M 27.89M 25.4M 23.41M 39.94M 2.58B 41.98M 285M 113M 1.41B 105M 102M 4.43B 25.07M 32.84M 29.91M 27.56M 47.03M 3.04B 49.43M 335M 133M 1.66B 123M 121M 5.21B
Projected Income Statement - Annual - Shield Therapeutics plc
Logo Shield Therapeutics plc
Shield Therapeutics plc is a United Kingdom-based commercial-stage pharmaceutical company. The Company delivers differentiated specialty pharmaceuticals that address a significant unmet need for patients suffering from iron deficiency, with or without anemia. The Company’s lead product, Accrufer/Feraccru, is broadly indicated for use in adults across multiple therapeutic categories. Ferric maltol is approved in the United States, European Union, the United Kingdom, Canada, Australia and Switzerland for the treatment of iron deficiency with or without anemia in adults. It also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co., Ltd., for the development and commercialization of ACCRUFeR/FeRACCRU in China, Hong Kong, Macau and Taiwan, with Korea Pharma Co., Ltd. for the Republic of Korea. The Company's subsidiaries include Phosphate Therapeutics Limited, Shield TX (Switzerland) AG, Shield Therapeutics Inc, and Shield TX (UK) Limited.
Employees
61
Date Price Change Volume
26-11-20 GBX 3.050 0.00% 2,444,745
26-11-19 GBX 3.050 0.00% 513,706
26-11-18 GBX 3.050 0.00% 227,915
26-11-17 GBX 3.050 +1.67% 1,496,647
26-11-16 GBX 3.000 -6.25% 2,314,066
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Shield Therapeutics plc
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.0305GBP
Average target price
0.1567GBP
Spread / Average Target
+413.67%

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Shield Therapeutics plc